Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash & Current Investments: 2016-2025

Historic Cash & Current Investments for Rhythm Pharmaceuticals (RYTM) over the last 9 years, with Sep 2025 value amounting to $780.1 million.

  • Rhythm Pharmaceuticals' Cash & Current Investments rose 161.02% to $780.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 88.86%. This contributed to the annual value of $321.0 million for FY2024, which is 16.24% up from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Cash & Current Investments stood at $780.1 million, which was up 74.73% from $446.4 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Cash & Current Investments ranged from a high of $780.1 million in Q3 2025 and a low of $201.7 million during Q1 2024.
  • For the 3-year period, Rhythm Pharmaceuticals' Cash & Current Investments averaged around $365.0 million, with its median value being $299.6 million (2023).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 621.05% in 2021, then plummeted by 40.43% in 2022.
  • Rhythm Pharmaceuticals' Cash & Current Investments (Quarterly) stood at $295.2 million in 2021, then climbed by 13.02% to $333.6 million in 2022, then dropped by 17.22% to $276.2 million in 2023, then climbed by 16.24% to $321.0 million in 2024, then skyrocketed by 161.02% to $780.1 million in 2025.
  • Its Cash & Current Investments was $780.1 million in Q3 2025, compared to $446.4 million in Q2 2025 and $522.9 million in Q1 2025.